AI Search: Truist Keeps Buy on Viking Therapeutics but Lowers Price Target
What happened
Truist Securities maintained its Buy rating on Viking Therapeutics but lowered its price target on the stock, according to a report from Benzinga. The reduced price target represents a downgrade in expectations for the biotech even as the firm continues to endorse the shares. Separately, it-boltwise reported that Viking Therapeutics has started a new study of its VK2735 candidate focused on weight maintenance, adding a fresh clinical development thread to the company's story at the same time the analyst action landed.
Why it matters for VKTX
The combination of the two developments frames the current narrative around the stock. On one hand, a maintained Buy rating signals that the covering analyst has not abandoned the investment thesis. On the other hand, a lowered price target is a step down in expectations, and expectation resets from covering analysts tend to weigh on sentiment even when the rating itself is unchanged. The new VK2735 weight maintenance study getting underway is a meaningful counterpoint, since it shows the pipeline advancing into a new phase of testing. For VKTX, the tension between a trimmed price target and ongoing clinical progress is what investors are now weighing.
How the market reacted
The stock moved down modestly following the news. The reaction came despite the broader market trading higher, which underscores that the analyst action, rather than general market conditions, was the primary driver of the move. Ezbrisk's read is that the market reaction reads as a fair reaction relative to the news — the price decline appears proportionate to a lowered price target paired with an unchanged rating and ongoing pipeline activity, rather than an overreaction in either direction.
What this news leaves open
Several questions remain. How much weight will the lowered price target carry with other analysts and investors, and will it prompt revisions elsewhere on the Street? What will the newly started VK2735 weight maintenance study show, and how quickly will any results influence sentiment? And can positive clinical momentum offset the reduced expectations embedded in the trimmed price target, or will analyst caution continue to weigh on the stock even as its pipeline advances?
Previous verdicts for VKTX
- VKTX drifts on trial news — 2026-10-06
- AI Search: Viking Therapeutics Slips Modestly on Dilutive Capital Raise — 2026-10-05
- VKTX Pulls Back — 2026-10-01
- VKTX Rides Obesity Data — 2026-09-30
- VKTX Calm After Raise — 2026-09-29
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works